Top
Skip to Content
LOGO(small) - Queen's University Belfast
  • Our x-twitter
  • Our facebook
LOGO(large) - Queen's University Belfast

Wellcome-Wolfson Institute For Experimental Medicine

  • Home
  • Our Research
    • Research Themes
    • Find a PhD Supervisor
  • Our People
    • Key Contacts
    • Academic Staff
    • Fellows
    • Research Staff
    • Technical Staff
    • Administrative/Clerical Staff
    • Emeritus Professors
    • Opportunities
    • Visiting Students
  • Our Place
    • Facilities
    • Seminar Series
    • The Barcroft Lecture
    • The Annual Kenneth B. Fraser Memorial Symposium in Infection Biology
    • Green Impact
  • Outreach
    • Balmoral Show
    • Northern Ireland Science Festival
    • Learn@Lunch 2022-2023
    • Pint of Science
    • UNISTEM Belfast 2025
    • Apply for Work Experience
    • Research Placements and Experiences - STEM Learning
    • NI Multiple Sclerosis Research Network
  • Education and Training
    • Postgraduate Degrees
    • Masters in Biomedical & Clinical Research
    • Undergraduate Degrees
    • Summer Student Programme
    • iEngage Online Summer Student Research Programme
    • Postdoctoral Development Programme
    • Short Courses
  • News
    • WWIEM Newsletter
  • Innovation
  • Impact
  • COVID-19
  • Donate
  • Home
  • Our Research
    • Research Themes
    • Find a PhD Supervisor
  • Our People
    • Key Contacts
    • Academic Staff
    • Fellows
    • Research Staff
    • Technical Staff
    • Administrative/Clerical Staff
    • Emeritus Professors
    • Opportunities
    • Visiting Students
  • Our Place
    • Facilities
    • Seminar Series
    • The Barcroft Lecture
    • The Annual Kenneth B. Fraser Memorial Symposium in Infection Biology
    • Green Impact
  • Outreach
    • Balmoral Show
    • Northern Ireland Science Festival
    • Learn@Lunch 2022-2023
    • Pint of Science
    • UNISTEM Belfast 2025
    • Apply for Work Experience
    • Research Placements and Experiences - STEM Learning
    • NI Multiple Sclerosis Research Network
  • Education and Training
    • Postgraduate Degrees
    • Masters in Biomedical & Clinical Research
    • Undergraduate Degrees
    • Summer Student Programme
    • iEngage Online Summer Student Research Programme
    • Postdoctoral Development Programme
    • Short Courses
  • News
    • WWIEM Newsletter
  • Innovation
  • Impact
  • COVID-19
  • Donate
  • Our x-twitter
  • Our facebook
In This Section
  • WWIEM Newsletter

  • Home
  • Wellcome-Wolfson Institute For Experimental Medicine
  • News

News

EU Commission highlights Wellcome Wolfson Institute for Experimental Medicine Research

17 December, 2018

With a better understanding of how Klebsiella Pneumoniae evades our body's immune system, researchers with the EU-funded U-KARE project are developing new treatments based on boosting our defences against the potentially deadly disease.

Although a relatively common infection, some bacteria that causes pneumonia can be particularly deadly. As a case in point, take Klebsiella pneumoniae, which has been included on the World Health Organisation’s (WHO) list of infections that desperately need new treatments.

What makes K.pneumoniae so problematic is the increasing number of antibiotic-resistant Klebsiella strains. Perhaps even more alarming is the number of strains with access to a pool of genes that can make Klebsiella hypervirulent – essentially a superbug capable of causing untreatable infections by breaking down a host’s protective mechanisms. With virtually no treatment available, Klebsiella has been singled out as an ‘urgent threat to human health.’

Addressing this threat is the EU-funded U-KARE project. “The goal of this project was to better understand the immune evasion strategies of K. pneumoniae and, from this understanding, develop new therapeutic strategies based on boosting our defences and clearing the infection,” explains U-KARE researcher Jose Bengoechea.

Landmark discoveries

During the course of the U-KARE project, Bengoechea and his team of researchers made several important breakthroughs. For instance, they discovered that Klebsiella can survive inside macrophages, which are the cells that play an essential part in our immune system’s ability to fight K. pneumoniae. “As the antibiotics we currently use are inefficient at targeting bacteria that live inside our cells, this finding has important clinical implications on how we treat Klebsiella infections,” explains Bengoechea.

Researchers also discovered just how sophisticated Klebsiella’s immune evasion strategy is. Essentially, the pathogen can manipulate the functioning of our cells, rendering the proteins we use to fight infections useless. “What we see is a close relationship between Klebsiella’s antibiotic resistance and its virulence, or ability to infect a resistant host,” says Bengoechea. “These findings emphasise the importance of evaluating both antibiotic resistance and virulence in order to better monitor a patient’s outcome.”

Last but not least, in a landmark discovery, researchers uncovered the crucial role that interferons play in defending against Klebsiella infections. Interferons are a group of signalling proteins made and released by a virus-infected cell that causes nearby cells to heighten their anti-viral defences. “Interferons activate macrophages and natural killer cells to control Klebsiella pneumonia,” explains Bengoechea. “What this finding means is that interferons could be considered for new therapeutics developments.”

A host-directed therapeutic approach

Based on this research, Bengoechea was able to establish a pre-clinical research programme in his laboratory. Here he and his team are developing new therapeutics based on boosting our own defences against Klebsiella infections. “I believe this host-directed therapeutic approach will limit the pathogen’s ability to develop resistance against new treatments,” adds Bengoechea. “We already obtained very promising results in animal models in which, without the need for antibiotics, we were able to reduce the infection by more than 80 %.”

U-KARE’s research is ongoing, with the next major milestone being the launch of clinical trials in humans. “Although we are still at the very early stages, these potential new treatments will have a major health impact, especially considering the increasing number of Klebsiella infections worldwide and the limited treatment options available,” concludes Bengoechea.

Full EU Research and Innovation story

Professor Jose Bengoechea
Share
Latest News
  • Queen’s academic awarded prestigious Professorship
    22 May, 2024
  • Professor Pascale Cossart of Institut Pasteur Receives Barcroft 2020 Medal
    4 May, 2022
  • Resource launched illustrating COVID-19 variants across Northern Ireland
    8 February, 2022
  • New research will focus on repurposing existing anti-viral therapies to treat patients with COVID-19
    31 January, 2022
  • Non-invasive ventilation for COVID-19 patients isn’t linked to heightened infection risk
    5 November, 2021
News
  • WWIEM Newsletter
QUB Logo
Contact Us

Wellcome-Wolfson Institute For Experimental Medicine

School of Medicine, Dentistry and Biomedical Sciences
Queen's University Belfast
97 Lisburn Road
Belfast
BT9 7BL

Tel: (+44) 028 9097 1643
Email: wwiem@qub.ac.uk

Quick Links

  • Home
  • Our Research
  • Our People
  • Our Place
  • Education and Training
  • Opportunities

 

© Queen's University Belfast 2024
  • Privacy and cookies
  • Website accessibility
  • Freedom of information
  • Modern slavery statement
  • Equality, Diversity and Inclusion
  • University Policies and Procedures
Information
  • Privacy and cookies
  • Website accessibility
  • Freedom of information
  • Modern slavery statement
  • Equality, Diversity and Inclusion
  • University Policies and Procedures

© Queen's University Belfast 2024

Manage cookies